ClinicalTrials.gg
RecruitingNCT07109375PEGASOUpdated Jul 8, 2026

Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world Setting

An observational study in Fabry Disease, sponsored by Chiesi Italia. Recruiting at 7 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Chiesi Italia (part of Chiesi Farmaceutici S.p.A.) · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
75
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A. — 5 open to participants now, 5 under way, 2 of them phase 3. Fabry Disease · Chiesi Farmaceutici S.p.A..

Started
2026
the only one that year
Observational
5 of 10
3 open now
Registered
10th of 10
by date

Among the 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A., this one is the only one that started in 2026, is one of 5 observational ones, and was the 10th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

5 of the 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A. are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Fabry Disease by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

PEGASO is an observational study designed to collect prospective data on the effectiveness and safety of pegunigalsidase alfa in adult patients with Fabry disease, being treated or planning to start treatment, under real-world setting.

03

Conditions studied

  • Fabry Disease

Keywords

  • Pegunigalsidase alfa
  • Fabry disease
  • Real-world
  • Alpha-galactosidase A
  • Lysosomal storage disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults patients who have a genetically confirmed diagnosis of Fabry disease and are being treated or plan to initiate treatment with pegunigalsidase alfa as per clinical practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female adults (≥ 18 years).
  2. Patients with a clinical diagnosis of Fabry disease confirmed by α-Gal A assay and detection of mutation in α-Gal A gene.
  3. Patients either taking or planning to take pegunigalsidase alfa as treatment for Fabry disease. The treatment decision must be made independently from participation in this study.
  4. Written to participate in the study and for the processing of personal data.

Exclusion criteria

Exclusion Criteria:

  1. History of reaction to pegunigalsidase alfa.
  2. Presence of any medical, emotional, behavioural, or psychological condition that, in the judgment of the physician, could interfere with the ability to participate in the study.
  3. Female subjects who are pregnant or planning to become pregnant during the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
75 participants (estimated)
Patient registry
No

Groups and cohorts

  • Fabry patients

    Adult patients whit genetically confirmed diagnosis of Fabry disease being treated or planning to start treatment with Pegunigalsidase alfa according to clinical practice. Participants will be required to meet the inclusion and exclusion criteria and sign informed consent to be enrolled in the study.

    Drug: pegunigalsidase alfa

Interventions

  • Pegunigalsidase alfa is 2 mg/mL concentrate for solution and is administered via intravenous infusion every two weeks.

    Also known as: Elfabrio

06

What researchers measure

Primary outcomes

  1. Assessment of structural abnormalities of the left ventricle

    Changes from baseline in structural abnormalities of the left ventricle assessed by echocardiography and defined by the presence of Left Ventricular Hypertrophy.

    Time frame: 24 months

  2. Assessment of left ventricular diastolic function

    Changes from baseline in left ventricular diastolic function by echocardiography. Diastolic dysfunction will be assessed using early to late diastolic trans-mitral flow velocity.

    Time frame: 12 and 24 months

  3. Assessment of renal function

    Changes from baseline in renal function by estimated Glomerular Filtration Rate.

    Time frame: 6, 12, 18 and 24 months

Secondary outcomes

  1. Assessment of peak oxygen uptake (pVO2)

    Changes from baseline in peak oxygen uptake (pVO2) using cardiopulmonary exercise testing (CPET).

    Time frame: 24 months

  2. Assessment of carbon dioxide production (VCO2)

    Changes from baseline in carbon dioxide production (VCO2) using cardiopulmonary exercise testing (CPET).

    Time frame: 24 months

  3. Assessment of NT-pro-BNP and high sensitivity cardiac troponin levels

    Changes from baseline in NT-pro-BNP and high sensitivity cardiac troponin levels.

    Time frame: 6, 12,18 and 24 months

  4. Assessment of Cardiovascular Magnetic Resonance (CMR)

    Changes from baseline in CMR assessed using T1 mapping to achieve myocardial tissue characterization.

    Time frame: 12 and 24 months

  5. Assessment of proteinuria and microalbuminuria

    Changes from baseline in proteinuria and microalbuminuria assessed on 24-hour urine sample.

    Time frame: 6, 12, 18 and 24 months

  6. Assessment of Globotriaosylsphingosine (lyso-Gb3)

    Changes from baseline in blood concentration of lyso-Gb3

    Time frame: 3, 6, 12 and 24 months

  7. Assessment of QoL outcomes using the Short Form Health Survey 36 (SF-36)

    Changes from baseline in SF-36 score. It is a disease-specific questionnaire consisting of eight domains, each represented by a scale calculated as the weighted sum of responses in the respective sections. Each domain score ranges from 0 to 100, with all questions given equal weight. A score of 0 indicates the worst possible health status, while a score of 100 represents the best possible health status.

    Time frame: 12 and 24 months

  8. Assessment of QoL outcomes using the Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Changes from baseline in KCCQ scores. It measures patient's perception of their health status, focusing on heart failure symptoms, the impact on physical and social functioning, and the overall effect of heart failure on their QoL within a 2-week recall period. It evaluates seven domains, with scores ranging from 0 to 100, where lower scores indicate more severe symptoms or limitations, while a score of 100 represents no symptoms, no limitations, and excellent quality of life.

    Time frame: 12 and 24 months

  9. Assessment of severity of neuropathic pain using Chronic Pain Grade (CPG)

    Changes from baseline in CPG score. It is a 7-item questionnaire that evaluates chronic pain severity experienced over the past six months. Pain intensity is rated from 0 (no pain) to 10 ("pain as bad as it can be"). Scores for pain intensity and disability are combined to classify the overall severity of chronic pain into four grades, ranging from Grade 0 (no pain) to Grade IV (high disability, severely limiting).

    Time frame: 12 and 24 months

  10. Assessment of severity of neuropathic pain using Short Form of the Brief Pain Inventory (BPI-SF)

    Changes from baseline in BPI-SF score. It is a 9-item questionnaire assessing Pain Intensity and Pain Interference, as its impact on daily functions, over the past 24 hours. Pain intensity is rated on a 0 (no pain) to 10 (pain as bad as you can imagine) scale, across four measures: worst, least, average, and current pain. Pain interference with daily activities is also scored from 0 (no interference) to 10 (completely interferes).

    Time frame: 12 and 24 months

  11. Assessment of gastrointestinal symptoms using the Gastrointestinal Symptoms Rating Scale (GSRS)

    Changes from baseline in GSRS score. It is a 15-item questionnaire designed to assess changes in gastrointestinal symptoms across five clusters: reflux, abdominal pain, indigestion, diarrhea, and constipation. The GSRS uses a seven-point Likert-type scale, with scores ranging from 1 (no troublesome symptoms) to 7 (very troublesome symptoms).

    Time frame: 12 and 24 months

  12. Assessment of specific Fabry disease ocular findings

    Number of patients with presence of specific Fabry disease ocular findings (i.e. cornea verticillate) by slit lamp

    Time frame: Baseline, 12 and 24 months

  13. Adverse events

    Number of AEs

    Time frame: 24 months

  14. Adverse drug reactions to pegunigalsidase alfa

    Number of ADRs

    Time frame: 24 months

  15. Anti-drug antibodies (ADAs) testing

    Number of patients with ADAs

    Time frame: 24 months

  16. Infusion-Related Reactions (IRRs)

    Number of patients and occurrence of IRRs

    Time frame: 24 months

07

Study locations

2 of 7 sites recruiting
  • AUSL Toscana Sud-Est - Ospedale San Donato
    Arezzo, Italy
    Not yet recruiting
    • Maurizio Pieroni, MD · Contact
    • Maurizio Pieroni · Principal investigator
  • Azienda Ospedaliera Universitaria Consorziale Policlinico Di Bari
    Bari, Italy
    Recruiting
    • Gesualdo · Contact
    • Loreto Gesualdo · Principal investigator
  • Irccs Azienda Ospedaliero-Universitaria Di Bologna - Policlinico Di Sant'Orsola
    Bologna, Italy
    Recruiting
    • La Manna · Contact
    • Gaetano La Manna · Principal investigator
  • A.O. Sant'Anna e San Sebastiano
    Caserta, Italy
    Not yet recruiting
    • Paolo Calabrò · Contact
    • Paolo Calabrò · Principal investigator
  • U.O.C. Nefrologia ASST Monza - Ospedale San Gerardo
    Monza, Italy
    Not yet recruiting
    • Federico Pieruzzi · Contact
    • Federico Pieruzzi · Principal investigator
  • AOU Federico II, Dipartimento di Nefrologia
    Naples, Italy
    Not yet recruiting
    • Antonio Pisani, MD · Contact+39 081 7464521
  • A.O.U. Policlinico "Giaccone"
    Palermo, Italy
    Not yet recruiting
    • Antonino Tuttolomondo, MD · Contact
    • Antonino Tuttolomondo · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Feb 2029, 32 months after the start.

Of 61 observational studies under Fabry Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 36. This study's planned 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2025
First posted
Aug 7, 2025
StartActual
Jun 15, 2026
Primary completionEst.
Feb 2029
CompletionEst.
Feb 2029
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07109375
Lead sponsor
Chiesi Italia
Responsible party
Sponsor
First posted
Aug 7, 2025
Start date
Jun 15, 2026
Primary completion
Feb 2029 (estimated)
Completion
Feb 2029 (estimated)
Last update
Jul 8, 2026

Study contacts

Chiesi Clinical Trial info
Contact
clinicaltrials_info@chiesi.com
+3905212791
Antonio Pisani, MD
principal investigator · AOU Federico II, Dipartimento di Nefrologia, Napoli, Italy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion